01586nas a2200265   4500000000100000008004100001260002500042653001200067100002300079700001300102700002300115700001300138700001400151700002100165700001300186700002100199700001600220700001500236245001200251856006800263300001400331490000800345520095300353022001401306       2026                            d  c01/2026bElsevier BV10aleprosy1 aAgudelo Higuita NI1 aAvanzi C1 aHenao-Martínez AF1 aHonap TP1 aBendera N1 aFranco-Paredes C1 aYotsu RR1 aRakotoarisaona M1 aManimozhi N1 aSpencer JS00aLeprosy  uhttps://www.tanvihonap.com/uploads/7/5/5/1/75514407/leprosy.pdf  a805 - 8190 v4073 a<p>Leprosy, also known as Hansen’s disease, is a curable granulomatous condition caused by Mycobacterium leprae or Mycobacterium lepromatosis, disproportionately affecting impoverished communities across the globe. The bacteria’s tropism for dermal histiocytes, endothelial cells, and Schwann cells causes neuronal and dermal damage that often results in disability, permanent disfigurement, stigma, and social exclusion. Despite important achievements in the understanding of the disease, its elimination has been hampered by the scarcity of sensitive diagnostic tools, suboptimal integration and implementation of coordinated and financially stable preventive interventions, persistent stigmatisation, and failure to efficiently and sustainably address the socioeconomic and demographic factors associated with an increased risk of leprosy. In this Seminar, we provide an update on key public health and clinical aspects of the disease.</p>
  a0140-6736